Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Incidence of Orbital Recurrence After Enucleation or Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma—Reply

Incidence of Orbital Recurrence After Enucleation or Ophthalmic Artery Chemosurgery for Advanced... Letters Funding/Support: Dr Klufas is supported for vitreoretinal surgery fellowship Eleven patients (17.5%) in the enucleation group had a training as a John and Theiline McCone Fellow at Stein Eye Institute, University higher-risk feature (postlaminar optic nerve invasion), but not of California, Los Angeles. all received adjuvant intravenous chemotherapy (9.5%). On the Role of the Funder/Sponsor: The funder had no role in the design and conduct other hand, some patients in the OAC group also received of the study; collection, management, analysis, and interpretation of the data; intravenous chemotherapy (6.5%) or radiotherapy (1.3%). preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Heterogeneity regarding systemic treatment between both 1. Kronenburg A, Braun KP, van der Zwan A, Klijn CJ. Recent advances in treatment groups might be an important confounder. moyamoya disease: pathophysiology and treatment. Curr Neurol Neurosci Rep. Nowadays, many centers perform pre-enucleation magnetic 2014;14(1):423. resonance imaging, which in our opinion greatly adds to pre- 2. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J treatment stage prediction of the affected eye(s) and justifies Med. 2009;360(12):1226-1237. a safe, conservative treatment approach in which no histopatho- 3. Williams M, Adas A, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Incidence of Orbital Recurrence After Enucleation or Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma—Reply

Loading next page...
 
/lp/american-medical-association/incidence-of-orbital-recurrence-after-enucleation-or-ophthalmic-artery-G7oVCJuzmb
Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2015.4581
pmid
26584063
Publisher site
See Article on Publisher Site

Abstract

Letters Funding/Support: Dr Klufas is supported for vitreoretinal surgery fellowship Eleven patients (17.5%) in the enucleation group had a training as a John and Theiline McCone Fellow at Stein Eye Institute, University higher-risk feature (postlaminar optic nerve invasion), but not of California, Los Angeles. all received adjuvant intravenous chemotherapy (9.5%). On the Role of the Funder/Sponsor: The funder had no role in the design and conduct other hand, some patients in the OAC group also received of the study; collection, management, analysis, and interpretation of the data; intravenous chemotherapy (6.5%) or radiotherapy (1.3%). preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Heterogeneity regarding systemic treatment between both 1. Kronenburg A, Braun KP, van der Zwan A, Klijn CJ. Recent advances in treatment groups might be an important confounder. moyamoya disease: pathophysiology and treatment. Curr Neurol Neurosci Rep. Nowadays, many centers perform pre-enucleation magnetic 2014;14(1):423. resonance imaging, which in our opinion greatly adds to pre- 2. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J treatment stage prediction of the affected eye(s) and justifies Med. 2009;360(12):1226-1237. a safe, conservative treatment approach in which no histopatho- 3. Williams M, Adas A,

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Jan 1, 2016

References